Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy

Jian-rong Wu, David H. Bremner, Shi-Wei Niu, Huanling Wu, Junzi Wu, Haijun Wang, Heyu Li, Li-Min Zhu

    Research output: Contribution to journalArticle

    18 Citations (Scopus)
    11 Downloads (Pure)

    Abstract

    The combination of different therapies into a single platform has attracted increasing attention as a potential synergistic tumor treatment. Herein, the fabrication of a novel folate targeted system for chemo-photothermal therapy by using thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs) as a drug-loading vehicle is described. The novel targeted molecular bovine serum albumin-folic acid-modified MoS2 sheets (MoS2-PEI-BSA-FA) were successfully synthesized and characterized, and then utilized as a capping agent to block PMOs to control the drug release and to investigate their potential in near-infrared photothermal therapy. The resulting PMOs–DOX@MoS2–PEI-BSA-FA complexes had a uniform diameter (196 nm); high DOX loading capacity (185 mg/g PMOs-SH); excellent photothermal transformation ability; and good biocompatibility in physiological conditions. The PMOs–DOX@MoS2–PEI-BSA-FA exhibited pH-dependence and near infrared (NIR) laser irradiation-triggered DOX release. In vitro experimental results confirmed that the material exhibits excellent photothermal transfer ability, outstanding tumor killing efficiency and specificity to target tumor cells via an FA-receptor-mediated endocytosis process. The in vivo experiments further demonstrated that the platform for synergistic chemo-photothermal therapy could significantly inhibit tumor growth, which is superior to any monotherapy. Meanwhile, cytotoxicity assays and histological assessments show that the engineered PMOs@MoS2–PEI-BSA-FA have good biocompatibility, further inspiring potential biomedical applications. Overall, this work describes an excellent drug delivery system for chemo-photothermal synergistic targeted therapy having good drug release properties, which have great potential in cancer therapy.
    Original languageEnglish
    Pages (from-to)90-102
    Number of pages13
    JournalChemical Engineering Journal
    Volume342
    Early online date12 Feb 2018
    DOIs
    Publication statusPublished - 15 Jun 2018

    Fingerprint

    chemotherapy
    Chemotherapy
    Nanosheets
    tumor
    Tumors
    drug
    Nanoparticles
    Biocompatibility
    Folic Acid
    near infrared
    Pharmaceutical Preparations
    Polyetherimides
    Infrared lasers
    capping
    Sulfides
    Laser beam effects
    Cytotoxicity
    Bovine Serum Albumin
    serum
    cancer

    Cite this

    Wu, Jian-rong ; Bremner, David H. ; Niu, Shi-Wei ; Wu, Huanling ; Wu, Junzi ; Wang, Haijun ; Li, Heyu ; Zhu, Li-Min. / Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy. In: Chemical Engineering Journal. 2018 ; Vol. 342. pp. 90-102.
    @article{125670f6f6d047959d6436d4e7e7a9d3,
    title = "Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy",
    abstract = "The combination of different therapies into a single platform has attracted increasing attention as a potential synergistic tumor treatment. Herein, the fabrication of a novel folate targeted system for chemo-photothermal therapy by using thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs) as a drug-loading vehicle is described. The novel targeted molecular bovine serum albumin-folic acid-modified MoS2 sheets (MoS2-PEI-BSA-FA) were successfully synthesized and characterized, and then utilized as a capping agent to block PMOs to control the drug release and to investigate their potential in near-infrared photothermal therapy. The resulting PMOs–DOX@MoS2–PEI-BSA-FA complexes had a uniform diameter (196 nm); high DOX loading capacity (185 mg/g PMOs-SH); excellent photothermal transformation ability; and good biocompatibility in physiological conditions. The PMOs–DOX@MoS2–PEI-BSA-FA exhibited pH-dependence and near infrared (NIR) laser irradiation-triggered DOX release. In vitro experimental results confirmed that the material exhibits excellent photothermal transfer ability, outstanding tumor killing efficiency and specificity to target tumor cells via an FA-receptor-mediated endocytosis process. The in vivo experiments further demonstrated that the platform for synergistic chemo-photothermal therapy could significantly inhibit tumor growth, which is superior to any monotherapy. Meanwhile, cytotoxicity assays and histological assessments show that the engineered PMOs@MoS2–PEI-BSA-FA have good biocompatibility, further inspiring potential biomedical applications. Overall, this work describes an excellent drug delivery system for chemo-photothermal synergistic targeted therapy having good drug release properties, which have great potential in cancer therapy.",
    author = "Jian-rong Wu and Bremner, {David H.} and Shi-Wei Niu and Huanling Wu and Junzi Wu and Haijun Wang and Heyu Li and Li-Min Zhu",
    year = "2018",
    month = "6",
    day = "15",
    doi = "10.1016/j.cej.2018.02.052",
    language = "English",
    volume = "342",
    pages = "90--102",
    journal = "Chemical Engineering Journal",
    issn = "1385-8947",
    publisher = "Elsevier",

    }

    Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy. / Wu, Jian-rong; Bremner, David H.; Niu, Shi-Wei; Wu, Huanling; Wu, Junzi; Wang, Haijun; Li, Heyu; Zhu, Li-Min.

    In: Chemical Engineering Journal, Vol. 342, 15.06.2018, p. 90-102.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy

    AU - Wu, Jian-rong

    AU - Bremner, David H.

    AU - Niu, Shi-Wei

    AU - Wu, Huanling

    AU - Wu, Junzi

    AU - Wang, Haijun

    AU - Li, Heyu

    AU - Zhu, Li-Min

    PY - 2018/6/15

    Y1 - 2018/6/15

    N2 - The combination of different therapies into a single platform has attracted increasing attention as a potential synergistic tumor treatment. Herein, the fabrication of a novel folate targeted system for chemo-photothermal therapy by using thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs) as a drug-loading vehicle is described. The novel targeted molecular bovine serum albumin-folic acid-modified MoS2 sheets (MoS2-PEI-BSA-FA) were successfully synthesized and characterized, and then utilized as a capping agent to block PMOs to control the drug release and to investigate their potential in near-infrared photothermal therapy. The resulting PMOs–DOX@MoS2–PEI-BSA-FA complexes had a uniform diameter (196 nm); high DOX loading capacity (185 mg/g PMOs-SH); excellent photothermal transformation ability; and good biocompatibility in physiological conditions. The PMOs–DOX@MoS2–PEI-BSA-FA exhibited pH-dependence and near infrared (NIR) laser irradiation-triggered DOX release. In vitro experimental results confirmed that the material exhibits excellent photothermal transfer ability, outstanding tumor killing efficiency and specificity to target tumor cells via an FA-receptor-mediated endocytosis process. The in vivo experiments further demonstrated that the platform for synergistic chemo-photothermal therapy could significantly inhibit tumor growth, which is superior to any monotherapy. Meanwhile, cytotoxicity assays and histological assessments show that the engineered PMOs@MoS2–PEI-BSA-FA have good biocompatibility, further inspiring potential biomedical applications. Overall, this work describes an excellent drug delivery system for chemo-photothermal synergistic targeted therapy having good drug release properties, which have great potential in cancer therapy.

    AB - The combination of different therapies into a single platform has attracted increasing attention as a potential synergistic tumor treatment. Herein, the fabrication of a novel folate targeted system for chemo-photothermal therapy by using thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs) as a drug-loading vehicle is described. The novel targeted molecular bovine serum albumin-folic acid-modified MoS2 sheets (MoS2-PEI-BSA-FA) were successfully synthesized and characterized, and then utilized as a capping agent to block PMOs to control the drug release and to investigate their potential in near-infrared photothermal therapy. The resulting PMOs–DOX@MoS2–PEI-BSA-FA complexes had a uniform diameter (196 nm); high DOX loading capacity (185 mg/g PMOs-SH); excellent photothermal transformation ability; and good biocompatibility in physiological conditions. The PMOs–DOX@MoS2–PEI-BSA-FA exhibited pH-dependence and near infrared (NIR) laser irradiation-triggered DOX release. In vitro experimental results confirmed that the material exhibits excellent photothermal transfer ability, outstanding tumor killing efficiency and specificity to target tumor cells via an FA-receptor-mediated endocytosis process. The in vivo experiments further demonstrated that the platform for synergistic chemo-photothermal therapy could significantly inhibit tumor growth, which is superior to any monotherapy. Meanwhile, cytotoxicity assays and histological assessments show that the engineered PMOs@MoS2–PEI-BSA-FA have good biocompatibility, further inspiring potential biomedical applications. Overall, this work describes an excellent drug delivery system for chemo-photothermal synergistic targeted therapy having good drug release properties, which have great potential in cancer therapy.

    U2 - 10.1016/j.cej.2018.02.052

    DO - 10.1016/j.cej.2018.02.052

    M3 - Article

    VL - 342

    SP - 90

    EP - 102

    JO - Chemical Engineering Journal

    JF - Chemical Engineering Journal

    SN - 1385-8947

    ER -